EASTERN COOPERATIVE ONCOLOGY GROUP

贝丝以色列女执事医疗中心(BIDMC)是1996年贝丝以色列和新英格兰女执事医院、两个邻居和位于朗伍德医疗区的主要哈佛医学院机构合并而成的。BIDMC的教职员工，以及新招聘的波士顿ECOG长期成员，现在包括了一批致力于临床癌症研究的特殊人员。作为CareGroup网络的主要高等教育/学术资源，BIDMC拥有一个自然和现成的ECOG网络，以增强其在癌症护理以及临床和基础科学研究方面的长期卓越传统。BIDMC是国家公认的专门技术中心的所在地，包括辐射联合中心(JCRT)、肝脏和其他固体器官移植、艾滋病和相关恶性肿瘤、乳腺癌/妇女健康、恶性黑色素瘤、医学信息学和临床试验方法、细胞因子和生物治疗。哈佛医学院(H.I.M.)位于附近，为合作小组翻译研究提供优秀的研究人员和基于实验室的部件。BIDMC于1997年5月加入ECOG，成为范德比尔特大学的附属机构。从97年5月至97年10月，BIDMC作为附属机构受理了36起案件。基于这一强有力的活动和在97年9月进行的一次完全令人满意的实地考察，BIDMC于97年10月被授予主要成员机构地位，并于1998年1月获准申请经社理事会核心赠款。从1997年10月至1997年12月，作为主要机构，北京疾病预防控制中心招募了19名患者参加ECOG研究。到目前为止，BIDMC在1998年已累积了33名病人，使97‘5月至98’5月的累积总数相当于88名病人。我们致力于在ECOG指定的癌症预防、诊断和治疗领域进行实验室和临床研究，并在过去证明了高水平的患者收益，并有潜力在未来做出更大贡献、小组科学和患者登记。

Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School institutions in the Longwood Medical Area. The BIDMC faculty, together with newly recruited long-time Boston-based ECOG members now includes an exceptional group of committed clinical cancer researchers. Serving as the principal tertiary/academic resources of the CareGroup Network, BIDMC has a natural and ready-made ECOG network to add to its long tradition of excellence in cancer care as well as both clinical and basic science research. BIDMC is home to nationally recognized centers of special expertise including the Joint Center for Radiation (JCRT), liver and other solid-organ transplantation, AIDS and related malignancies, breast cancer/women's health, malignant melanoma, medical informatics and clinical trials methodology, cytokine and biologic therapy. The Harvard Institute of Medicine (H.I.M.) Located nearby provides outstanding research scientists and laboratory-based components for cooperative group translational research. BIDMC joined ECOG as an affiliate of Vanderbilt University in May 1997. From May '97-October '97, as an affiliate, BIDMC entered 36 cases. Based on this strong activity and a fully satisfactory site visit in September '97, BIDMC was granted Main Member Institution status in October '97 and approved to apply for an ECOG Core Grant in January 1998. From October '97 to December '97, as a main institution, BIDMC enrolled 19 patients to ECOG studies. To date, in 1998 BIDMC has accrued 33 patients, making the total accrual for May '97 to May '98 equal to 88 patients. We are committed to conducting laboratory and clinical research in the ECOG specified areas of cancer prevention, diagnosis, and treatment and have demonstrated high levels of patient accrual in the past and have the potential for even greater contributions, group science, and patient enrollment in the future.